Virtus Investment Advisers, Inc. Taysha Gene Therapies, Inc. Transaction History
Virtus Investment Advisers, Inc.
- $286 Million
- Q2 2025
A detailed history of Virtus Investment Advisers, Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Virtus Investment Advisers, Inc. holds 35,484 shares of TSHA stock, worth $184,516. This represents 0.03% of its overall portfolio holdings.
Number of Shares
35,484
Previous 72,957
51.36%
Holding current value
$184,516
Previous $101,000
19.8%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding TSHA
# of Institutions
155Shares Held
244MCall Options Held
107KPut Options Held
17K-
Rtw Investments, LP New York, NY25MShares$130 Million0.89% of portfolio
-
Ra Capital Management, L.P. Boston, MA23.6MShares$122 Million1.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY21.7MShares$113 Million0.91% of portfolio
-
Morgan Stanley New York, NY16.9MShares$87.7 Million0.0% of portfolio
-
Octagon Capital Advisors LP New York, NY12.6MShares$65.5 Million11.04% of portfolio
About Taysha Gene Therapies, Inc.
- Ticker TSHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,359,500
- Market Cap $251M
- Description
- Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...